Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Glycolysis-associated lncRNAs identify a subgroup of cancer patients with poor prognoses and a high-infiltration immune microenvironment

Fig. 1

Identification of glycolysis-associated long noncoding (lnc)RNAs and their roles in cancer prognoses. a A flowchart demonstrating our investigation of glycolysis-associated lncRNAs and their putative functions in cancers. b Kaplan–Meier plots indicating patient survival rates of distinct clusters stratified by glycolysis-associated lncRNAs in five cancer types. Right panel presents glycolysis scores in different clusters. Cancer patients were clustered into groups based on glycolysis-associated lncRNAs by performing a consensus clustering analysis. Optimal clusters were selected by judging delta area plots where no appreciable increase was evident. Validation of the clinical importance of these glycolysis-associated lncRNAs was derived from genomic classifiers from independent GEO data including GSE16011 and GSE107850 for gliomas (c) and GSE13507 and GSE48075 for bladder cancer (d). Kaplan–Meier plots demonstrate patient survival rates of different groups. The right panel displays glycolysis scores in different clusters. TCGA, The Cancer Genome Atlas; GSEA, gene set enrichment analysis; PCG, protein coding gene; TF, transcription factor; BLCA, bladder carcinoma; LGG, low-grade glioma; MESO, mesothelioma; PAAD, pancreatic ductal adenocarcinoma; UVM, uveal melanoma

Back to article page